These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: A label-free, ultra-highly sensitive and multiplexed SERS nanoplasmonic biosensor for miRNA detection using a head-flocked gold nanopillar.
    Author: Kim WH, Lee JU, Song S, Kim S, Choi YJ, Sim SJ.
    Journal: Analyst; 2019 Feb 25; 144(5):1768-1776. PubMed ID: 30672519.
    Abstract:
    Cell-free micro-ribonucleic acids (cf-miRNAs) regulate most human genes by controlling the mRNA translation and have been considered as the most promising biomarkers for cancer diagnosis and prognosis. Due to their low abundance, short length, and similar sequences, an attractive approach that is ultrasensitive and label-free is highly demanded. Herein, we develop a label-free, ultra-high sensitivity and selectivity multiplex miRNA using surface-enhanced Raman scattering to detect cancer-associated miRNAs with head-flocked gold nanopillars as a substrate. Using a complementary DNA probe platform and an ultra-high sensitivity SERS based biosensor, we achieved high selectivity in targeting miRNAs with extremely low detection limits, without any chemical or enzymatic reactions and evaluated the correlation between the miRNA expression level and the Raman signal intensity. A reproducible SERS signal is monitored via uniformly fabricated elastic head-flocked gold nanopillars through a mapping method. This system supports the detection of cell-free miRNAs in blood, which are utilized and quantified as biomarkers to diagnose and provide a prognosis for cancers and intractable diseases. In the foreseeable future, this advanced label-free miRNA detection system is highly promising for a less tumor-invasive biopsy for the early diagnosis and prognosis of cancer.
    [Abstract] [Full Text] [Related] [New Search]